Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999-2014

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Alpha-1 antitrypsin and granulocyte colony-stimulating factor as serum biomarkers of disease severity in ulcerative colitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Multiple risk factors for diabetes mellitus in patients with chronic pancreatitis: A multicentre study of 1117 cases

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Association of multiple patient and disease characteristics with the presence and type of pain in chronic pancreatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sygdomme i pancreas

    Research output: Chapter in Book/Report/Conference proceedingBook chapterResearchpeer-review

  • Mette Julsgaard
  • Christian L Hvas
  • Richard B Gearry
  • Peter R Gibson
  • Jan Fallingborg
  • Miles P Sparrow
  • Bo M Bibby
  • William R Connell
  • Steven J Brown
  • Michael A Kamm
  • Ian C Lawrance
  • Thea Vestergaard
  • Lise Svenningsen
  • Mille Baekdal
  • Heidi Kammerlander
  • Alissa Walsh
  • Trine Boysen
  • Peter Bampton
  • Graham Radford-Smith
  • Jens Kjeldsen
  • Jane M Andrews
  • Kavitha Subramaniam
  • Gregory T Moore
  • Nanna M Jensen
  • Susan J Connor
  • Signe Wildt
  • Benedicte Wilson
  • Kathrine Ellard
  • Lisbet A Christensen
  • Sally J Bell
View graph of relations

BACKGROUND: Active inflammatory bowel disease (IBD) adversely affects pregnancy outcomes. Little is known about the risk of relapse after stopping anti-tumor necrosis factor (anti-TNF) treatment during pregnancy. We assessed the risk of relapse before delivery in women who discontinued anti-TNF treatment before gestational week (GW) 30, predictors of reduced infant birth weight, a marker associated with long-term adverse outcomes, and rates and satisfaction with counseling.

METHODS: Pregnant women with IBD receiving anti-TNF treatment were prospectively invited to participate in an electronic questionnaire carried out in 22 hospitals in Denmark, Australia, and New Zealand from 2011 to 2015. Risk estimates were calculated, and birth weight was investigated using t tests and linear regression.

RESULTS: Of 175 women invited, 153 (87%) responded. In women in remission, the relapse rate did not differ significantly between those who discontinued anti-TNF before GW 30 (1/46, 2%) compared with those who continued treatment (8/74, 11%; relative risk, 0.20; 95% confidence interval [CI], 0.02 to 1.56; P = 0.08). Relapse (P = 0.001) and continuation of anti-TNF therapy after GW 30 (P = 0.007) were independently associated with reduced mean birth weight by 367 g (95% CI, 145 to 589 g; relapse) and 274 g (95% CI, 77 to 471 g; anti-TNF exposure after GW 30). Of 134 (88%) women who received counseling, 116 (87%) were satisfied with the information provided.

CONCLUSIONS: To minimize fetal exposure in women in remission, discontinuation of anti-TNF before GW 30 seems safe. Relapse and continuation of anti-TNF therapy after GW 30 were each independently associated with lower birth weight, although without an increased risk for birth weight <2500 g. Most women received and were satisfied with counseling.

Original languageEnglish
JournalInflammatory Bowel Diseases
Volume26
Issue number1
Pages (from-to)93-102
Number of pages10
ISSN1078-0998
DOIs
Publication statusPublished - 1 Jan 2020

    Research areas

  • anti–tumor necrosis factor alpha, counseling, inflammatory bowel disease, pregnancy, pregnancy outcome

ID: 57450069